Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMX3009 in advanced or metastatic non-small cell lung cancer with uncommon EGFR mutations
CTR20241058Phase 2Active
- Sponsor
- Anrun Pharma
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AMX3009 in non-small cell lung cancer (NSCLC), sponsored by Anrun Pharma. Started Jun 2024; status: active.
02
Drugs
AMX3009
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20241058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241058.